**Site Master File HOT-COVID**

**Table of contents**

|  |  |
| --- | --- |
| **1.** | **Protocol and trial synopsis**  a) Approved protocol  b) Approved amendments  c) Trial synopsis |
| **2.** | **CRF** |
| **3.** | **Trial Participants**  a) Delegation- and signature log  b) Training log  c) Curriculum Vitae for all personnel |
| **4.** | **Approvals and correspondence**  a) Danish Medicines Agency  b) EudraCT  c) The Committees on Health Research Ethics  d) The Danish Data Protection Agency (Datatilsynet)  e) National and local approvals (site specific)  f) Annual Safety Report |
| **5.** | **Collaboration agreement**  a) Collaboration agreement between Sponsor and site  b) Approval from head of department  c) Other relevant contracts (site specific) |
| **6.** | **Financial affairs**  a) Case money  b) Patient insurances (site specific) |
| **7.** | **Information to participants**  a) Patient information  b) Consent forms (site specific) |

|  |  |
| --- | --- |
| **8.** | **Co-enrolment and substudies**  a) Co-enrolment form  b) Quality criteria for substudies  c) Substudy proposal form |
| **9.** | **Trial documents**  a) Trial instructions  b) Pocket cards, documents for a notice board in the department  c) Educational material (power point presentations) |
| **10.** | **Trial medication**  a) Summary of product characteristics |
| **11.** | **Laboratory tests** |
| **12.** | **Primary data source** |
| **13.** | **Communication**  a) HOT-COVID Contact details  b) Contact details – eight countries  c) Note to file sent to Sponsor  d) Note to file received from Sponsor  e) Other correspondences between Sponsor and site(s) (site specific)  f) Newsletters  g) Investigator meeting |
| **14.** | **Suspected unexpected serious adverse reactions**  a) SUSAR form  b) Standard operating procedure for SUSAR reporting  b) Documentation for reporting of SUSAR (site specific) |

|  |  |
| --- | --- |
| **15.** | **GCP unit**  a) Contacts (monitors/GCP units) (site specific)  b) Monitoring visits  c) Monitoring reports (site specific)  d) Monitoring plan  e) Approval of trial initiation (site specific)  f) Correspondence with the monitor (e.g. GCP-unit) (site specific) |
| **16.** | **Trial completion** |
| **17.** | **Appendices** |